GSK (BUE:GSK) Beta: N/A (As of Jun. 26, 2026)


BUE:GSK GSK PLC BUE:GSK
65 GF Score
Price ARS19,930.00
GF Value ARS16,498.50
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), GSK's Beta is Not available.

GSK  (BUE:GSK) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

GSK Beta Related Terms

GSK Beta Historical Data

* Premium members only.

The historical data trend for GSK's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Beta Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BUE:GSK
65GF Score
GSK PLC BUE:GSK
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is GSK (BUE:GSK) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of ARS19,930.00 is trading 20.8% above its estimated GF Value™ of ARS16,498.50. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for BUE:GSK:

  • Beta: N/A
  • GF Value™: ARS16,498.50 vs. price of ARS19,930.00 (20.8% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the BUE:GSK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
65GF Score

Get the complete analysis for BUE:GSK

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS19,930.00
Price
ARS16,498.50
GF Value